Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subject haslong termstrokesubject iscriteria subject
  Phrases that lowered it: patientsand safetyefficacy andevaluatesafety of
• Phase: 3 (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Design: single group (raises risk) · Design
• Sponsor's past termination rate: 6.9% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 88 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Sponsor's past trials: 173 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness NCT01028950 · started 2009 · scored riskier than 42% of active trials completed
• Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities NCT00937911 · started 2009 · scored riskier than 14% of active trials completed
• The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients NCT00911157 · started 2008 · scored riskier than 36% of active trials completed
• API-CAT STUDY for APIxaban Cancer Associated Thrombosis NCT03692065 · started 2018 · scored riskier than 74% of active trials completed
• A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery NCT00942435 · started 2009 · scored riskier than 27% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.